Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2021
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Therapeutic Use
- Acronyms OPUS
- Sponsors Biogen
- 14 Sep 2021 Results assessing the efficacy and safety of natalizumab as adjunctive therapy in drug-resistant focal epilepsy published in the Neurology
- 01 May 2021 Results analyzing electronic diary (e-diary) in OPUS trial to explore the efficacy, safety, and tolerability of natalizumab as adjunctive therapy in adult participants with drug-resistant focal epilepsy, published in the Epilepsy and Behavior.
- 17 Mar 2021 Results characterizing the ER relationship of natalizumab in focal epileptic patients presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics